The U.S. Food and Drug Administration granted marketing clearance for Ryplazim as the first FDA-approved therapy for the treatment of patients with the plasminogen deficiency type 1 (hypoplasminogenia), a rare genetic disorder.

China’s CanSino Biologics Inc. said the efficacy rate for the company’s single-dose Covid-19 vaccine may fall over time although it should still have a rate of 50 percent or more five to six months after inoculation.

Novavax Inc.’s Covid-19 vaccine was 96 percent effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on March 11, moving it a step closer to regulatory approval.

The results are in from Johnson & Johnso’s global Phase III ENSEMBLE clinical trial, and the company’s single-shot vaccine is 66% effective overall in preventing moderate-to-severe Covid-19, 28 days after vaccination.

The new Covid-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, according to scientists.

Final results from Pfizer Inc.’s Covid-19 vaccine trial showed the company’s shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days.

Johnson & Johnson secured more than $1 billion in additional funding for the company’s Covid-19 vaccine research through an expansion of J&J’s partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services.

Pfizer Inc.’s experimental Covid-19 vaccine was more than 90% effective based on initial trial results, the company said, a major victory in the fight against a pandemic that has killed more than 1 million people and battered the world’s economy.

An AstraZeneca executive said he felt encouraged by “incredibly promising” large-scale Covid-19 vaccine trial results unveiled by New York-based Pfizer and the company’s German partner BioNTech.

ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV acquisition in women  Findings follow data from HPTN 083, a partner HIV prevention […]